<?xml version="1.0"?>
<rdf:RDF
    xmlns:ctsaip="http://vivo.ufl.edu/ontology/ctsaip/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:pvs="http://vivoweb.org/ontology/provenance-support#"
    xmlns:core="http://vivoweb.org/ontology/core#"
    xmlns:vitroApp="http://vitro.mannlib.cornell.edu/ns/vitro/0.7#"
    xmlns:score="http://vivoweb.org/ontology/score#"
    xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
    xmlns:j.0="http://vivoweb.org/harvester/" > 
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24503724">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24503724"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24503724"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24503724">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24503724"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503724"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24503182">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24503182"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24503182"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500436">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500436"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500436"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500354">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500354"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500354"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/institution/University of Pennsylvania">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Organization"/>
    <rdfs:label>University of Pennsylvania</rdfs:label>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24503210"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24503182"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/3489">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/3489"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/3489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500657">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500657"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500657"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24503737">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24503737"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503737"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24503182">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24503182"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503182"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500758">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders</rdfs:label>
    <ctsaip:internalCaseNo>1534</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500758</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of the inventors: Martha Welch M.D., David Ruggiero Ph.D., Muhammad Anwar&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Description: Novel multipeptide regimens and associated kits comprising a combination of secretin and oxytocin for use in treating and/or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain are described.&lt;br /&gt;&lt;br /&gt;The pharmaceu...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500758"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/institution/Tufts University">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Organization"/>
    <rdfs:label>Tufts University</rdfs:label>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24503724"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24503737"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500758">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500758"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500758"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/casemngr/sayyidf@mail.nih.gov">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdfs:label>Fatima Sayyid</rdfs:label>
    <core:email>sayyidf@mail.nih.gov</core:email>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/3489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500445">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500445"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500445"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24499788">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24499788"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24499788"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500399">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500399"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500399"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500758">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500758"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500758"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500763">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Universal donor yeast strain for transfer of genetic material</rdfs:label>
    <ctsaip:internalCaseNo>1669</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500763</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of the inventor: Rodney J. Rothstein Ph.D&lt;br /&gt;&lt;br /&gt;A high-efficiency method to transfer extrachromosomal genetic material such as plasmid DNA into any Saccharomyces strain for use with the current gene disruption libraries is described.&lt;br /&gt;&lt;br /&gt;The yeast cell comprises of chromosomes I through XVI, at least two of which comprise a nucleic acid sequence encod...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500763"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/3489">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Development of Gene Chip Technology for Vascular Risk Assessment</rdfs:label>
    <ctsaip:internalCaseNo>E-030-2005/0</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=3489</core:webpage>
    <bibo:abstract>Prevention of cardiovascular disorders such as myocardial infarction and stroke is an area of major public health importance.  Currently, several risk factors for future cardiovascular disorders have been described and are in wide clinical use in the detection of individuals at high risk.  However a large number of cardiovascular disorders occur in individuals with apparently low to moderate risk profiles, thereby limiting the ability to identify such patients.  Moreover, many of the risk factors require accurate gathering of clinical information.  An objective panel of biological markers which allow one to predict an individual’s risk of vascular disease is therefore needed. 

The present provisional patent application is directed to utilizing blood mononuclear cells to evaluate vascular disease risk and determine a preventive regimen for reduction or minimization of such risk.  The method includes screening for differential expression of vascular risk-related molecules, such as DNA binding/transcription factor proteins, lysosomal or protein degradation enzymes, adhesion molecules, metabolism molecules, intracellular signaling molecules, immune response molecules and apoptosis.  The technology is available to a collaborator for monitoring stroke treatment protocols, for definition of clinical trial protocol candidates, or for developing an "assessment chip" that could be used to predict an individual’s risk of developing a stroke in the future. 

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors:  The NINDS Stroke Neuroscience Unit is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a vascular risk genetic chip technology.  We seek a collaborative partner in the development of a chip that could be used to predict an individual's risk of developing a stroke in the future and to monitor the effectiveness of preventive measures once they have been instituted.  Please contact Heather Gunas at gunash@mail.nih.gov for more information.
</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/sayyidf@mail.nih.gov"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/NIH"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/3489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24499788">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				Angelos D. Keromytis, PhD.&lt;/a&gt;&lt;br&gt; &lt;br&gt;</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24499788"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24499788"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/3489">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/3489"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/3489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500584">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Low voltage track and hold circuits</rdfs:label>
    <ctsaip:internalCaseNo>M05-089</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500584</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of the inventors: 	&lt;a href="http://www.cisl.columbia.edu/kinget_group/"&gt;Peter Kinget, Ph.D.; Shouri Chatterjee &lt;br /&gt;&lt;br /&gt;Circuits that operate with supply voltages near/lower than the threshold voltage of the transistors and capable of operating with power supplies of less than 1 Volt. &lt;br /&gt;&lt;br /&gt;A track and hold circuit having an input and an output comprise an operational transconductance amplifier (OTA). The output of an operationa...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500584"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500436">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500436"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500436"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24503210">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <rdfs:label>Pregnancy Up-Regulated, Nonubiquitous Cam Kinase (PNCK), 
Specific Marker for a Subset of Primary Human Breast Cancers</rdfs:label>
    <ctsaip:internalCaseNo>O2740</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24503210</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Pregnancy Up-Regulated Nonubiquitous Cam Kinase</bibo:abstract>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/University of Pennsylvania"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503210"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500445">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Insulin 2 GFP mouse</rdfs:label>
    <ctsaip:internalCaseNo>2363</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500445</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of the principal inventor:  Argiris Efstratiadis&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Research into the insulin- producing beta cell of the pancreas and the expression and secretion of insulin may offer avenues for the development of future treatments for diabetes mellitus, which affects at least 16 million Americans. Insulin synthesis and secretion is regulated by a complicate...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500445"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500399">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>DNAs encoding taurine and GABA transporters, LPA receptor</rdfs:label>
    <ctsaip:internalCaseNo>1852-1856</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500399</core:webpage>
    <ctsaip:advantages>* Novel genes
* Promising therapeutic target
* Many potential indications</ctsaip:advantages>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>*Problem or Unmet Need*
GABA is the major inhibitory neurotransmitter in the CNS. Maintenance of proper GABA levels prevents epileptic seizures. Inhibitors of GABA, taurine, and related tranporters may represent an important class of therapeutics for the treatment of epilepsy, migraine, ischemia, myoclonus, spasticity, and chronic pain.

Lysophosphatidic acid (LPA) is a glycerophospholipid whose signaling is involved in cell proliferation, neurite retraction, platelet agregation, smooth muscle contraction, tumor cell invasion, neurotransmitter release, chloride efflux, and chemotaxis. LPA receptors are important potential therapeutic targets for cancer, autoimmune disease, ischemia-reperfusion injury, thrombosis, neuropathic pain, infertility, even hair loss.

*Details of the Invention*
Patents for the technologies below were awarded to Synaptic Pharmaceutical Corporation between the years 1996-2001, and later donated to Columbia University.
	Mammalian (rat) taurine transporter gene
	Mammalian (rat) and human GABA transporter genes GAT-2 and GAT-3
	Human betaine/GABA transporter hBGT-1 gene, and methods for identifying compounds that bind the transporter
	Mammalian rB21a orphan transporter gene
	Human LPA receptor gene</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500399"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24502807">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24502807"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24502807"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24502807">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Novel Periostin Inhibitory Reagents Promote Myocardial Regeneration and Reduce Cardiac Scarring</rdfs:label>
    <ctsaip:internalCaseNo>P0905</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24502807</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 11pt"&gt;Coronary heart disease is the leading cause of death in 
the America. While one American death in every five annually is caused by 
coronary heart disease, treatment options remain limited.Â  Once injury to 
the heart occurs, the cardiac healing process is dominated by scar tissue 
formation. This leads to a diminished function of the damaged heart as a blood 
pump and increased risk of cardiac arrhythmia and sudden death. The exciting 
prospect of this licensing opportunity is that it is a potential therapy that 
would encourage the regeneration of heart muscle rather than scar tissue 
following a heart attack. A successful and safe approach to regenerative repair 
of the heart would truly revolutionize the standard of care for patients 
suffering from coronary heart disease.
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 11pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 11pt"&gt;This invention involves an innovative new strategy for 
modifying the behavior of stem cells in vivo to promote re-growth and/or 
repopulation of myocytes following heart attack.Â  As part of this novel 
approach, researchers at the Medical University of South Carolina have found 
that by blocking a key protein, scars that normally form in place of damaged 
myocardial tissue are reduced and, in turn, there is: (i) infiltration of new 
myocytes, (ii) proliferation of resident myocytes, and/or (iii) differentiation 
of stem cells into new myocytes (Figure).Â  This technology provides 
for regenerating new myocytes in vivo following a heart attack, and as 
such, would beÂ a treatment for enhancing and maintaining cardiac integrity, 
function, and viability following cardiac injury.Â Â  

&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Application and Advantages:
&lt;div style="TEXT-INDENT: -6mm; MARGIN: 0mm 0mm 0mm 15mm" align="justify"&gt;
&lt;font color="#010101" face="Symbol"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Â·Â Â Â Â &lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Differentiation, proliferation, and repopulation of 
cardiac scars with NEW functional myocytes

&lt;div style="TEXT-INDENT: -6mm; MARGIN: 0mm 0mm 0mm 15mm" align="justify"&gt;
&lt;font color="#010101" face="Symbol"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Â·Â Â Â Â &lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Novel therapy 
for patients post heart-attack

&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Inventors: Dr. R. Norris; Dr. R.G. Gourdie; Mr. 
M. P. O'Quinn; and Dr. R. R. Markwald
&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Patent Status: US Utility Paent 
Application Pending
&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Technology development status: In vivo 
animal model
&lt;div align="justify"&gt;
&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Availability: Available for exclusive, or 
non-exclusive licensing.Â Â ]]&amp;gt;</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/hoodwc@musc.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Medical University of South Carolina"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24502807"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500354">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Utilization of artificial human lipids for cosmetic and pharmaceutical dermal applications</rdfs:label>
    <ctsaip:internalCaseNo>1955-Dermal</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500354</core:webpage>
    <ctsaip:advantages>Easily scalable recombinant lipid production 
	Lipid chain length and saturation customizable for optimal stability and solubility 
	More closely mimics the natural lipids produced by human skin 
	Can be used to replace fats and waxes derived from animal </ctsaip:advantages>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>*Problem or Unmet Need*

Many of the products produced for cosmetic and pharmaceutical dermal applications contain lipids derived from plant and animal sources. These are complex mixtures of waxes and oils that do not necessarily provide the optimal profile for a particular application and may contain lipids which are not preferred to be in the formulation. Isolation of specific lipids from these mixtures can be cost-inhibitory for commercial production. Additionally, the lipids from these sources contain compounds not native to humans and therefore may not be ideal for products designed to interact with human skin. The ability to produce specific human lipids in a large-scale and cost-effective manner would be beneficial for all industries that utilize lipids. 


*Details of the Invention*

Drs. Sturley, Trokel and Turkish developed a technology that utilizes a yeast expression system deficient in its own lipid biosynthesis pathways to generate human lipids from introduced human enzyme genes, creating a biphasic solution containing aqueous and lipid components, which mimic natural human lipids. As the lipids to be produced can be individually selected, this system allows control over the components of a generated human lipid mixture. After growing the yeast population to a sufficient density, the lipids are harvested and purified for inclusion in a therapeutic or cosmetic treatment.</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500354"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24503210">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24503210"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503210"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24503737">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Novel Small Molecule Inhibitors of Bacterial Cell Division Efficacious at Lethal and Sub-lethal Concentrations</rdfs:label>
    <ctsaip:internalCaseNo>T001143</ctsaip:internalCaseNo>
    <core:webpage>http://www.tufts.biz/cgi-bin/tech_search.cgi?r=1&amp;case=T001143</core:webpage>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24503737</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Tufts University Categories:therapeutic:antibioticAdditional Keywords:(none specified)Invention SummaryNOVEL SMALL MOLECULE INHIBITORS OF BACTERIAL CELL DIVISION EFFICACIOUS AT LETHAL AND SUB-LETHAL CONCENTRATIONSTufts Case T001143; HU Case 1872Business OpportunitySmall molecule inhibitors of FtsZ, an essential and highly conserved bacterial cell division protein, have been identified through a protein-based as well as a chemical genetic whole-cell screen. These inhibitors can be used individually at lethal doses and also in a combinatorial approach at sub-lethal doses.  Combinatorial synthetic lethality creates new opportunities for effective anti-bacterial therapy, while diminishing the possibility of spontaneous drug resistance.Identification of Novel Cell Division InhibitorsCollaborative research between Harvard and Tufts Universities has validated the cell division target FtsZ using an in vitro and a chemical genetic whole-cell screen and identified novel small molecule inhibitors against this essential target that belong to three distinct chemical scaffolds. The Escherichia coli cell-based screen has yielded two broad classes of inhibitors: (a) molecules that cause lethal cell filamentation and inhibit FtsZ GTPase in vitro (FtsZ-specific inhibitors) and (b) molecules that induce cell filamentation and death without affecting the biochemical properties of FtsZ in any significant way.  The phenotypes caused by class (b) molecules suggest that they may target essential division proteins other than FtsZ (non-FtsZ inhibitors).â€¢The FtsZ-specific inhibitors identified and their three chemical scaffolds could serve as leads for an antibacterial drug development program.â€¢Analogues of the FtsZ-specific inhibitors should allow for composition of matter claims. These FtsZ-specific inhibitors would be used individually at lethal doses.â€¢Some of the FtsZ-specific inhibitors currently identified and protected by use claims may be appropriate for a drug development program.â€¢The in vitro and a chemical genetic whole-cell assays could be licensed separately on a non-exclusive basis.Combinatorial Approach at Sub-Lethal ConcentrationsThe portfolio of inhibitors identified in the above screens that target FtsZ and other septation proteins in the cell division pathway were tested for their ability to cause synergistic bacterial killing at sub-lethal doses.  The multiprotein septal ring is critical for bacterial division and is a dynamic structure; therefore, it was hypothesized that simultaneous partial inhibition of two or more essential proteins residing in the septal ring could lead to synergistic inhibition of cell division and cell growth. Results demonstrated that FtsZ-specific inhibitors used in binary combinations with non-FtsZ inhibitors killed E. coli cells at sub-lethal concentrations that were significantly lower than the individual MIC of each inhibitor.AdvantagesThe combinatorial synthetic lethality approach provides the following advantages:â€¢Allows lower doses of compounds to be used; therefore, it would significantly reduce the chances of spontaneous resistance arising in bacteria against the binary or tertiary combinations of inhibitors.â€¢Is adaptable for high throughout screening, allowing for an efficient exploration of the small-molecule combinatorial space and a full exploitation of the potential of small chemical libraries.â€¢Creates an exciting approach for novel anti-bacterial therapy through combinations with clinically proven antibiotics. One of the conserved bacterial cell division genes is ftsI that codes for the penicillin-binding protein (PBP) 3 in E. coli. The FtsZâ€“specific and â€“nonspecific septation inhibitors identified could be combined effectively with beta-lactam antibiotics that have high affinity for septation-specific PBP 3.â€¢Renders low potency molecules effective anti-bacterial agents when used in binary combinations.â€¢Requires only sub-lethal concentrations to be used for each inhibitor  to achieve partial inhibition; therefore it augments target selectivity by minimizing the effects of inhibitors on low-affinity secondary targets in the bacterial cell.â€¢Reduces the therapeutic dosage level required of each compound and hence the potential for drug cytotoxicity in the host. Ongoing and Future Studiesâ€¢Structural analogues of certain FtsZ-specific inhibitors are being synthesized and tested for improved activity in SAR studies.â€¢Studies on FtsZ antagonism and specific mechanism of action.â€¢Identification of cellular targets of class (b) molecules (non-FtsZ inhibitors).â€¢Studies currently in the planning stage would strive to solve the co-crystal structure of FtsZ complexed with small molecule FtsZ-specific inhibitors. Intellectual Property:  Issued US Patent No. 7,011,946T. Published US Patent Application No. 2003-0138869-A1 and 2003-0017521-A1.Primary Inventors: Debabrata RayChaudhuri, PhD, Tufts University School of Medicine and Marc Kirschner, PhD, Harvard University.Opportunity:  This technology is available for exclusive licensing and sponsored research. The high-throughput assays may be licensed separately.For further information contact:John CosmopoulosSenior Manager, Business DevelopmentTel. (617) 636-0366Fax: (617) 636-2917Email: John.Cosmopoulos@tufts.edu</bibo:abstract>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Tufts University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503737"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500436">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Improved Fixation of Orthopedic and Dental Implants</rdfs:label>
    <ctsaip:internalCaseNo>2208</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500436</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of the primary inventor:  Jeremy Mao.  &lt;br /&gt;&lt;br /&gt;Invention: Implant design and biomaterials for improved, long-term fixation of bone prostheses. &lt;br /&gt;Unmet Need: Current implants consist of inert, solid prosthetics, with or without surface indentations to promote host tissue ingrowth.  Even with surface modifica...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500436"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24499788">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <rdfs:label>Instrumentation for Predictive Application Failures</rdfs:label>
    <ctsaip:internalCaseNo>M04-065</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24499788</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Lead Inventor:	&lt;a href="http://www1.cs.columbia.edu/~angelos/"&gt;Angelos D. Keromytis, PhD. Tech Ventures Reference:	IR M04-065, IR M05-081, IR M05-082Problem or Unmet Need:Software applications are among those things we expect to be instrumented, i.e. ...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24499788"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24502803">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24502803"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24502803"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500763">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500763"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500763"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500399">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500399"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500399"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500763">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500763"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500763"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/institution/Medical University of South Carolina">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Organization"/>
    <rdfs:label>Medical University of South Carolina</rdfs:label>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24502807"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24502803"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500041">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Novel class of compounds for targeted photodelivery of therapeutic substances</rdfs:label>
    <ctsaip:internalCaseNo>M09-102</ctsaip:internalCaseNo>
    <core:webpage>http://www.twophoton.com</core:webpage>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500041</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Lead Inventors: Rafael Yuste, M.D., Ph.D., Roberto Etchenique, Ph.D., Luis Baraldo, Ph.D.

Tech Ventures Reference: M09-102 &amp; M04-031

Problem or Unmet Need
In photodynamic therapy (PDT), light energy is used to induce a chemical reaction of a specifically-designed photosensitive drug. Using this method, the effects of the drug can be precisely targeted to the tissue of interest. Currently, PDT is used to treat...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500041"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500041">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500041"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500041"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24502803">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24502803"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24502803"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500584">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500584"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500584"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24502807">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24502807"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24502807"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24503737">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24503737"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24503737"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/institution/Columbia University">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Organization"/>
    <rdfs:label>Columbia University</rdfs:label>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500354"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500399"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500763"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500436"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500445"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500657"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500758"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500584"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24499788"/>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500041"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24502803">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>A Method for the Detection and Monitoring of Bladder Cancer</rdfs:label>
    <ctsaip:internalCaseNo>P0804</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24502803</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 11pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 11pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Disclosed are methods for identifying a novel receptor 
(&lt;font color="#000000"&gt;thromboxane receptor Î² (TPÎ²)) present on human 
urological cancers. Investigators at the Medical University of South Carolina 
have found a receptor that is expressed on cancerous cells, but not normal human 
cells.Â  
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Furthermore, this receptor is sloughed off the cancerous 
cells and is expressed in the urine and prostatic fluid.Â  Human urine 
samples of patients positive for various degrees of bladder cancer confirm 
sensitivity approaching 93%, with a 100% specificity.
&lt;div align="justify"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Â 
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Technology development status: Human urine 
samples with biopsy confirmation
&lt;div align="left"&gt;
&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Â 
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Inventors:Â  Moussa, Watson, 
Haluska
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Patent Status:Â US Utility Application Ser No 
12/253,593Â (MUSC-FRD #P0804)
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;&lt;a href="http://www.google.com/patents/about?id=_BjHAAAAEBAJ&amp;amp;dq=12/253,592"&gt;http://www.google.com/patents/about?id=_BjHAAAAEBAJ&amp;amp;dq=12/253,592
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;Availability: Available for exclusive, or 
non-exclusive licensing.
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="left"&gt;&lt;font color="#010101" face="Times New Roman"&gt;&lt;span style="FONT-SIZE: 12pt"&gt;
&lt;div align="left"&gt;Â Â ]]&amp;gt;</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/hoodwc@musc.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Medical University of South Carolina"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24502803"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24503210">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24503210"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24503210"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500584">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500584"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500584"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500657">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500657"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500657"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24500657">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Novel antioxidant in the treatment and prevention of lung disease</rdfs:label>
    <ctsaip:internalCaseNo>1999</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24500657</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Name of principal inventor: Jeanine D'armiento&lt;br /&gt;&lt;br /&gt;Problem or Unmet Need:&lt;br /&gt;Chronic obstructive pulmonary disease (COPD) is a lung disease caused by cigarette use. It is the fourth leading cause of death in America; and has 11.4 million affected adults. Approximately $20.9 billion is spent annually on COPD treatment. COPD has a poor prognosis since no t...</bibo:abstract>
    <ctsaip:caseManager rdf:resource="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu"/>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Columbia University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500657"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500354">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500354"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500354"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24503182">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Technology"/>
    <rdfs:label>Hyperbaric Treatment in Wound Healing</rdfs:label>
    <ctsaip:internalCaseNo>S4256</ctsaip:internalCaseNo>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24503182</core:webpage>
    <ctsaip:advantages>Hyperbaric Oxygen therapy is currently in use and the addition of SDF-1a increases the rate of wound closure
</ctsaip:advantages>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>SDF-1a for the Treatment of Chronic Skin Wounds</bibo:abstract>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/University of Pennsylvania"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503182"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/casemngr/TechTransfer@columbia.edu">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdfs:label>Tech Transfer</rdfs:label>
    <core:email>TechTransfer@columbia.edu</core:email>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500354"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500399"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500763"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500436"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500445"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500657"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500758"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500584"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24499788"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24500041"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/author/24500445">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdf:type rdf:resource="http://vivoweb.org/harvester/excludeEntity"/>
    <rdfs:label></rdfs:label>
    <foaf:firstName></foaf:firstName>
    <foaf:lastName></foaf:lastName>
    <core:linkedInformationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/tech/24500445"/>
    <core:authorInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24500445"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/institution/NIH">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Organization"/>
    <rdfs:label>NIH</rdfs:label>
    <ctsaip:originatingInstitutionFor rdf:resource="http://vivoweb.org/harvest/ip/tech/3489"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/authorship/24500041">
    <rdf:type rdf:resource="http://vivoweb.org/ontology/core#Authorship"/>
    <rdfs:label>Authorship for 
				</rdfs:label>
    <core:linkedAuthor rdf:resource="http://vivoweb.org/harvest/ip/author/24500041"/>
    <core:linkedInformationResource rdf:resource="http://vivoweb.org/harvest/ip/tech/24500041"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/tech/24503724">
    <rdf:type rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <vitroApp:mostSpecificType rdf:resource="http://vivo.ufl.edu/ontology/ctsaip/Innovation"/>
    <rdfs:label>Vaccine Development for Pathogenic Gram-Negative Bacteria and Carrier for the Heterologous Expression of Proteins</rdfs:label>
    <ctsaip:internalCaseNo>T001244</ctsaip:internalCaseNo>
    <core:webpage>http://www.tufts.biz/cgi-bin/tech_search.cgi?r=1&amp;case=T001244</core:webpage>
    <core:webpage>http://www.ctsaip.org/details.cfm?id=24503724</core:webpage>
    <bibo:status>Published</bibo:status>
    <bibo:abstract>Tufts University Categories:therapeutic:vaccineAdditional Keywords:(none specified)Invention SummaryBusiness OpportunityResearch at Tufts University demonstrated that disruption of the Yersinia ysc genes, responsible for type III secretion systems, reduces or eliminates secretion of Yersinia outer proteins (Yops), thereby decreasing or eliminating virulence. Disruption of the type III secretion system represents a novel strategy for the development of vaccines for a variety of pathogenic Gram-negative bacteria. The attenuated Yersinia strain may also be used to introduce heterologous antigens into the mesenteric lymph nodes.InventionYersinia pseudotuberculosis was used for proof of principle experiments that demonstrated that disruption of its ysc genes, responsible for type III secretion systems, reduces or eliminates secretion of Yops, thereby decreasing or eliminating virulence. Disruption of type III secretion system of Gram-negative bacteria, which prevents the bacteria from secreting their respective virulence factors, represents a novel strategy for the development of vaccines for a variety of pathogenic Gram-negative bacteria. These include: Chlamydia, Pseudomonas, Vibrio, Salmonella, Shigella, and pathogenic E. coli strains such as enterotoxigenic (ETEC), enteropathogenic (EPEC), enterohemorrhagic (EHEC), venous thromboses-producing (VTEC), and enteroinvasive (EIEC) strains.The attenuated Y. pseudotuberculosis strain that was developed colonizes the mesenteric lymph nodes as well as the wild type strain. Therefore, this strain may represent a novel and innovative bacterial vehicle to express and/or secrete heterologous proteins, transport these antigens into the mesenteric lymph nodes and present them to the immune system to facilitate an immune response.Applications-The invention provides a strategy to created avirulent strains for use as vaccines for a variety of Gram-negative pathogenic bacteria including: Chlamydia, Pseudomonas, Vibrio, Salmonella, Shigella, Bordetella and pathogenic E. coli species.The attenuated Y. pseudotuberculosis strain currently developed also presents the following applications:-Vaccine for humans for Y. pestis.-Vaccine for animal health applications to protect against infections by Y. pestis, Y. pseudotuberculosis, Y. enterocolitica and Y. ruckeri.-Bacterial vehicle for transporting and expressing heterologous antigens into the mesenteric lymph nodes.Intellectual Property:U.S. patent application has been filed.Inventors:Joan Mecsas, PhD, Joan-Miquel Balada-Llasat and Ralph Isberg, PhD, Tufts University School of Medicine.Opportunity:This technology is available for exclusive licensing for all fields, an exclusive license by field and sponsored research.Published US patent application: 2005/0136075</bibo:abstract>
    <ctsaip:originatingInstitution rdf:resource="http://vivoweb.org/harvest/ip/institution/Tufts University"/>
    <core:informationResourceInAuthorship rdf:resource="http://vivoweb.org/harvest/ip/authorship/24503724"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://vivoweb.org/harvest/ip/casemngr/hoodwc@musc.edu">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdfs:label>Chip Hood</rdfs:label>
    <core:email>hoodwc@musc.edu</core:email>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24502807"/>
    <ctsaip:caseManagerFor rdf:resource="http://vivoweb.org/harvest/ip/tech/24502803"/>
  </rdf:Description>
</rdf:RDF>
